Rocket Pharmaceuticals(US:RCKT) GlobeNewswire News Roomยท2025-06-23 12:30Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the safety and clinical trial protocol for its drug RP-A501, which is intended for the treatment of Danon disease [4][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of investors who purchased Rocket securities between February 27, 2025, and May 26, 2025 [4]. - Allegations include that the defendants made false statements about the safety of RP-A501 and failed to disclose serious adverse events, including participant deaths during the clinical trial [5]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file their papers by August 11, 2025, with the understanding that participation as a lead plaintiff is not necessary to share in any potential recovery [6]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [6]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation, being recognized multiple times by The National Law Journal and The Legal 500 [7].